24 August 2018

Consortium Pediatric Praziquantel played an important role at the 15th International Symposium on Schistosomiasis in Brazil

Latest achievements presented by the Pediatric Praziquantel Consortium partners, Farmanguinhos and Merck, at the 15th International Symposium on Schistosomiasis on August 1-3, 2018 (Rio de Janeiro, Brazil)

The global health and scientific schistosomiasis community met in Rio de Janeiro at the occasion of the 15th International Symposium on Schistosomiasis

Amongst a series of topics covered at the conference, the presentations given by Dr Daniel Lacerda de Oliveira (from Farmanguinhos, Brazil) and Dr Elly Kourany-Lefoll, the Program Lead (from MGaA, Darmstadt, Germany) on the progresses of the Consortium program from a process development/manufacturing and clinical perspectives (currently completing Phase II), raised significant interest.  The panel discussion on ‘schistosomiasis in preschool-age children’ showcased the importance of this program to fill the treatment gap for this very young population and to contribute to the control and elimination agendas.  Partners’ booth throughout the symposium also allowed to exchange additional details on the program.

At the occasion of the symposium, a series of meetings were held to exchange with partners and regulators in Brazil in order to prepare for the next registration and access phases of the program.  All with the common target to provide access to the new pediatric orodispersible tablet formulation to this vulnerable population of children in the coming years.